Shots:

• Treventis to receive up front, research funding, option exercise, clinical and commercial milestones of ~$372.5M upon achievement along with royalties on net sales of any commercial product
• Takeda also gets an option to exclusively license the program globally for the development and commercialization of the tau program. The molecules were developed by the team at Treventis, building upon the Alzheimer’s & neurodegenerative research expertise
• Researchers at Treventis developed a proprietary platform technology called Common Conformational Morphology (CCM) which uses computer-aided modeling to design molecules that can prevent the pathogenic misfolding of no. of different proteins at the earliest stages

Ref: PR Newswire | Image: Takeda